For patients with moderate to end-stage CKD, elobixibat is associated with improvement in constipation and lipid metabolism, according to a study published in Frontiers in Medicine. For the study, researchers retrospectively analyzed stool frequency and serum lipid parameters before and after 4 weeks of elobixibat administration. Regardless of whether patients were undergoing dialysis, were on concomitant laxatives, or were administered elobixibat before or after breakfast, elobixibat increased stool frequency from 0.5 ± 0.4 to 1.1 ± 90.6 per day. In addition, there was a reduction in low-density lipoprotein cholesterol concentration with elobixibat, while high-density lipoprotein cholesterol concentration increased and there was no change in triglyceride concentration. After initiation of elobixibat, only phosphate concentration correlated with the change in stool frequency. “We found that elobixibat improved constipation and lipid metabolism in patients with renal impairment, without serious adverse events,” the authors wrote.